We request continued support for the Yale Cancer Center and the continued recognition as an NCI designated comprehensive cancer center. The major focus of the Center is in molecular medicine and the application of the new biology into the clinics to bring about progress in the prevention, diagnosis and treatment of cancer. In this application we request support for 14 research programs, five of which are new restructured programs focusing on specific diseases or scientific thrusts that bridge laboratory and clinical research efforts (Cancer Genetics, Genetic Therapy/Medical Oncology and Hematology, Stem Cell Biology and Transplant, Breast Cancer Research Lymphoma Research), and 14 shared resources, six of which are new since the last application (Biostatistics, Medical Informatics, Rapid Case Ascertainment, Genetic Therapy Human Applications, Genetic Counseling and Gene Targeting Service). In addition a new research program on prostate cancer has been established and supported by YCC, and three former research programs and one shared resource have been phases out. Since the last application a strong recruiting effort has led to restaffing of several YCC programs, and changes in leadership and administrative structure of the Center. We request support for the senior leadership, program directors at a level that reflects their actual time commitment to the center and its programs and for sufficient administrative staff to ensure the continued smooth functioning of the YCC and its evolution as a comprehensive cancer center. The YCC has a robust research base of a total of $54 million dollars in peer reviewed funding of which $13.9 million dollars comes from NCI grants exclusive of the CCSG. Since the last submission major changes have also resulted in a more substantial clinical trials program with strong support for data management and Biostatistics and the establishment of a clinical trials network (The Yale Oncology Network or YON), that will allow the YCC members the flexibility to test the impact of their research results on the practical applications for people with cancer in the YCC catchment area including the undeserved populations in the sphere of influence of YON institutions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-26
Application #
6172669
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1977-12-01
Project End
2003-06-30
Budget Start
2000-07-01
Budget End
2001-06-30
Support Year
26
Fiscal Year
2000
Total Cost
$1,987,599
Indirect Cost
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331
De Feyter, Henk M; Behar, Kevin L; Corbin, Zachary A et al. (2018) Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of metabolism in vivo. Sci Adv 4:eaat7314
Ventura, Alessandra; Vassall, Aaron; Robinson, Eve et al. (2018) Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity. Cancer Res 78:4045-4058
Xiao, Qian; Wu, Jibo; Wang, Wei-Jia et al. (2018) DKK2 imparts tumor immunity evasion through ?-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med 24:262-270
Jagannath, Sundar; Laubach, Jacob; Wong, Ellice et al. (2018) Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol 182:495-503
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :
Chae, Wook-Jin; Bothwell, Alfred L M (2018) Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside. Front Immunol 9:303
Kim, Hanseul; Keum, NaNa; Giovannucci, Edward L et al. (2018) Garlic intake and gastric cancer risk: Results from two large prospective US cohort studies. Int J Cancer 143:1047-1053

Showing the most recent 10 out of 675 publications